Design, synthesis, and biochemical and computational screening of novel oxindole derivatives as inhibitors of Aurora A kinase and SARS-CoV-2 spike/host ACE2 interaction
Medicinal Chemistry Research · 2024-04 · 33 (4) · 620-634
DOI: 10.1007/s00044-024-03201-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicinal Chemistry Research, online erschienen am 05.03.2024. Verfasst von Donatus B Eni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Bill and Melinda Gates Foundation, Alexander von Humboldt-Stiftung.
Abstract (Originalsprache)
Isatin (indol-2,3-dione), a secondary metabolite of tryptophan, has been used as the core structure to design several compounds that have been tested and identified as potent inhibitors of apoptosis, potential antitumor agents, anticonvulsants, and antiviral agents. In this work, several analogs of isatin hybrids have been synthesized and characterized, and their activities were established as inhibitors of both Aurora A kinase and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike/host angiotensin-converting enzyme II (ACE2) interactions. Amongst the synthesized isatin hybrids, compounds 6a , 6f , 6g , and 6m exhibited Aurora A kinase inhibitory activities (with IC 50 values < 5 $$\mu$$ μ M), with GScore values of −7.9, −7.6, −8.2 and −7.7 kcal/mol, respectively. Compounds 6g and 6i showed activities in blocking SARS-CoV-2 spike/ACE2 binding (with IC 50 values in the range < 30 $$\mu$$ μ M), with GScore values of −6.4 and −6.6 kcal/mol, respectively. Compounds 6f , 6g , and 6i were both capable of inhibiting spike/ACE2 binding and blocking Aurora A kinase. Pharmacophore profiling indicated that compound 6g tightly fits Aurora A kinase and SARS-CoV-2 pharmacophores, while 6d fits SARS-CoV-2 and 6l fits Aurora A kinase pharmacophore. This work is a proof of concept that some existing cancer drugs may possess antiviral properties. Molecular modeling showed that the active compound for each protein adopted different binding modes, hence interacting with a different set of amino acid residues in the binding site. The weaker activities against spike/ACE2 could be explained by the small sizes of the ligands that fail to address the important interactions for binding to the ACE2 receptor site.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon.
- Department of Chemistry, Faculty of Science, University of Buea, Buea, Cameroon.
- The Wistar Institute, Philadelphia, PA USA.
- Institute of Pharmacy, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
ORCID-Profile: Donatus B Eni, Joel Cassel, Cyril T Namba-Nzanguim, Conrad V Simoben, Ian Tietjen, Ravikumar Akunuri, Joseph M Salvino, Fidele Ntie-Kang
Förderung
- NCI NIH HHS
- Bill and Melinda Gates Foundation
- Alexander von Humboldt-Stiftung
- LifeArc
Zitieren
APA
Eni, D. B., Cassel, J., Namba-Nzanguim, C. T., Simoben, C. V., Tietjen, I., Akunuri, R., Salvino, J. M., & Ntie-Kang, F. (2024). Design, synthesis, and biochemical and computational screening of novel oxindole derivatives as inhibitors of Aurora A kinase and SARS-CoV-2 spike/host ACE2 interaction. Medicinal Chemistry Research, 33(4), 620-634. https://doi.org/10.1007/s00044-024-03201-7
Vancouver
Eni DB, Cassel J, Namba-Nzanguim CT, Simoben CV, Tietjen I, Akunuri R, et al. Design, synthesis, and biochemical and computational screening of novel oxindole derivatives as inhibitors of Aurora A kinase and SARS-CoV-2 spike/host ACE2 interaction. Medicinal Chemistry Research. 2024;33(4):620-634. doi:10.1007/s00044-024-03201-7
BibTeX
@article{Eni2024,
author = {Eni, Donatus B and Cassel, Joel and Namba-Nzanguim, Cyril T and Simoben, Conrad V and Tietjen, Ian and Akunuri, Ravikumar and Salvino, Joseph M and Ntie-Kang, Fidele},
title = {Design, synthesis, and biochemical and computational screening of novel oxindole derivatives as inhibitors of Aurora A kinase and SARS-CoV-2 spike/host ACE2 interaction},
journal = {Medicinal Chemistry Research},
year = {2024},
volume = {33},
number = {4},
pages = {620--634},
doi = {10.1007/s00044-024-03201-7}
}
EUVIMED